Premium
Drug Susceptibilities of Isolates of Varicella‐Zoster Virus in a Clinical Study of Oral Brovavir
Author(s) -
Machida Haruhiko,
Nishitani Makiko
Publication year - 1990
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1990.tb01023.x
Subject(s) - varicella zoster virus , virus , virology , biology , drug , pharmacology
Susceptibilities to brovavir [l‐β‐D‐arabinofuranosyl‐ E ‐5‐(2‐bromovinyl)‐uracil] and acyclovir of clinical isolates of varicella‐zoster virus obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method. All 101 isolates were significantly susceptible to brovavir; 50% effective dose of brovavir for these isolates ranged between 0.6‐4.0 ng/ ml (average: 1.29 ng/ml). Brovavir was about 3,000 times more potent than acyclovir against these isolates. No marked change in the susceptibility of isolates from these patients during treatment with brovavir was observed.